Research & understanding of the human genome in recent years has given insight into new, more effective treatments for a variety of diseases. The cornerstone of NGM RxHealth is pharmacogenomic testing, or ‘PGx’. Pharmacogenomic testing is a non-invasive, highly informative medical tool that identifies genetic variations in the human genome that directly correlate to the patient’s ability to metabolize drugs. These variations are the reason that the same drug at the standard acceptable dose works well for one patient, has little effect in another, and in the worst cases, has a toxic result. Adverse Drug Events (ADEs) create serious burden to patient quality of life and the healthcare system. Each year, ADEs add $289 billion to healthcare costs, and are the 4th leading cause of death. Annual data from the U.S. Center for Disease Control and Prevention, and the Journal of the American Medical Association cite 2.2 million adverse drug reactions; and 100,000 deaths occurring from properly prescribed drugs. Current medication prescribing practices rely on trial-and-error periods to determine medication efficacy. This period is the point at which ADEs often occur. At NGM RxHealth, we believe that incorporating PGx testing into routine clinical practice is key to avoiding ADEs, decreasing healthcare costs, and most importantly, improving patient quality of life. In numerous studies and publications, PGx testing has shown these promising results. It is necessary to continue …